CSBR (Champions Oncology) YoY EBITDA Growth: 36.36% (As of Jul. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSBR Champions Oncology Inc CSBR
62 GF Score
Price $5.10
GF Value $6.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology YoY EBITDA Growth?

Champions Oncology CSBR +0.09% 62 YoY EBITDA Growth is 36.36% as of Jul. 2026. GuruFocus rates CSBR with a GF Score™ of 62/100 and a GF Value™ of $6.51 (Modestly Undervalued). The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Champions Oncology's YoY EBITDA Growth for the quarter that ended in Jul. 2026 was 36.36%.

Champions Oncology's EBITDA per Share for the three months ended in Jul. 2026 was $-0.01.

Champions Oncology YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Champions Oncology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology YoY EBITDA Growth Chart

Champions Oncology Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.06 -203.16 -128.83 221.98 -94.51

Champions Oncology Quarterly Data
Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26 Jul26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -108.66 -54.32 -103.81 84.44 36.36
CSBR
62GF Score
Champions Oncology Inc CSBR
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Champions Oncology's YoY EBITDA Growth for the fiscal year that ended in Apr. 2026 is calculated as:

YoY EBITDA Growth (A: Apr. 2026 )
=(EBITDA per Share (A: Apr. 2026 )-EBITDA per Share (A: Apr. 2025 ))/ | EBITDA per Share (A: Apr. 2025 ) |
=(0.025-0.455)/ | 0.455 |
=-94.51 %

Champions Oncology's YoY EBITDA Growth for the quarter that ended in Jul. 2026 is calculated as:

YoY EBITDA Growth (Q: Jul. 2026 )
=(EBITDA per Share (Q: Jul. 2026 )-EBITDA per Share (Q: Jul. 2025 )) / | EBITDA per Share (Q: Jul. 2025 )) |
=(-0.007--0.011)/ | -0.011 |
=36.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 36.36% mean?
Champions Oncology (CSBR) has a YoY EBITDA Growth of 36.36% as of Jul. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Champions Oncology and its competitors.
Is Champions Oncology's YoY EBITDA Growth too high?
Champions Oncology's current YoY EBITDA Growth is 36.36%. Overall, Champions Oncology has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's YoY EBITDA Growth compare to PLRX and IBIO?
Champions Oncology's YoY EBITDA Growth of 36.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Champions Oncology and its competitors. Champions Oncology's current YoY EBITDA Growth is 36.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.51, compared to a current price of $5.10 — trading 21.7% below its estimated fair value. The current YoY EBITDA Growth is 36.36%. Champions Oncology's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Champions Oncology (CSBR), the current YoY EBITDA Growth is 36.36% as of Jul. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $5.10 is trading 21.7% below its estimated GF Value™ of $6.51. GuruFocus considers Champions Oncology to be Modestly Undervalued.

Key valuation signals for CSBR:

  • YoY EBITDA Growth: 36.36%
  • GF Value™: $6.51 vs. price of $5.10 (21.7% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
62GF Score

Get the complete analysis for CSBR

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.10
Price
$6.51
GF Value